Benchmark analyst Bill Sutherland raised the firm’s price target on Agilon Health (AGL) to $4 from $3 and keeps a Buy rating on the shares following what the firm describes as a “largely in-line 4Q print and an appropriately cautious outlook for FY25.” FY25 is “a transition year” with reduced AEBITDA loss guidance on a targeted roughly 4% decline in Medicare Advantage membership as the company exits two unprofitable physician partnerships, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health’s Strategic Positioning and Financial Outlook Justify Buy Rating
- Cautious Hold Rating on Agilon Health Amid Uncertainty and Cost Challenges
- Agilon Health price target raised to $3 from $2 at Stifel
- Agilon Health Faces Strategic Adjustments Amid Part D Challenges, Hold Rating Issued
- Agilon Health: Navigating Financial Challenges with Strategic Adjustments Amid Hold Rating